neoSurgical, LTD. is pleased to report the execution of an exclusive distribution agreement with a global partner for the commercialization of neoClose® within Europe. The partner is a world leader in laparoscopic surgery with an extensive product portfolio available worldwide. This agreement anticipates initial product launch in Europe in May 2017.
Ronan Keating, neoSurgical’s CTO, stated, “This agreement is an important milestone for our company and our pursuit of advancing surgical wound healing. The quality of our European partner, their longstanding dedication to patient wellbeing, and their ambitions for the products in the marketplace are a testament to the efficacy and benefit of neoClose®.”
neoClose® brings a simple, intuitive and reliable solution to assist the surgeon in closing port site defects, up to 3cm, following laparoscopic abdominal surgery. By utilizing bio-absorbable anchors and a Vector-X closure, neoClose® is changing the standard of care in port site closure.
